These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28318222)

  • 21. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
    Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
    Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of JAK1, JAK2, and JAK3 in Functional Stimulation of Mesenchymal Precursor Cells by Alkaloid Songorine.
    Zyuz'kov GN; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM; Chaikovskii AV; Agafonov VI; Zhdanov VV
    Bull Exp Biol Med; 2017 Aug; 163(4):443-446. PubMed ID: 28853089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibitors of the Janus kinase Jak3--Are they effective?
    Thoma G; Drückes P; Zerwes HG
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
    Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
    [No Abstract]   [Full Text] [Related]  

  • 26. Treating inflammation with the Janus kinase inhibitor CP-690,550.
    Vijayakrishnan L; Venkataramanan R; Gulati P
    Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
    Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
    Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells.
    Zgheib A; Pelletier-Bonnier É; Levros LC; Annabi B
    Cytokine; 2013 Aug; 63(2):187-93. PubMed ID: 23688618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
    He L; Pei H; Lan T; Tang M; Zhang C; Chen L
    Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
    Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
    Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
    Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
    Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
    Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
    J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
    Clark MP; George KM; Bookland RG; Chen J; Laughlin SK; Thakur KD; Lee W; Davis JR; Cabrera EJ; Brugel TA; VanRens JC; Laufersweiler MJ; Maier JA; Sabat MP; Golebiowski A; Easwaran V; Webster ME; De B; Zhang G
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1250-3. PubMed ID: 17189692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
    Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
    J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
    Dai J; Yang L; Addison G
    Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
    Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
    ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Jak3 deficiency blocks innate lymphoid cell development.
    Robinette ML; Cella M; Telliez JB; Ulland TK; Barrow AD; Capuder K; Gilfillan S; Lin LL; Notarangelo LD; Colonna M
    Mucosal Immunol; 2018 Jan; 11(1):50-60. PubMed ID: 28513593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors.
    Zhong HA; Almahmoud S
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
    Kim BH; Yi EH; Jee JG; Jeong AJ; Sandoval C; Park IC; Baeg GH; Ye SK
    J Cell Mol Med; 2020 Jul; 24(13):7427-7438. PubMed ID: 32558259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.
    van Gurp EA; Schoordijk-Verschoor W; Klepper M; Korevaar SS; Chan G; Weimar W; Baan CC
    Transplantation; 2009 Jan; 87(1):79-86. PubMed ID: 19136895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.